BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 24992512)

  • 1. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
    Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Kawamura K; Wada H; Nakasone H; Akahoshi Y; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Sato M; Tanihara A; Kimura SI; Kako S; Kanda Y
    Transplant Cell Ther; 2021 May; 27(5):436.e1-436.e8. PubMed ID: 33775586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients.
    Lin RY; Anderson AD; Morris MI; Raja M; Komanduri KV; Camargo JF
    Transpl Infect Dis; 2023 Apr; 25(2):e14043. PubMed ID: 36880572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.
    Randi BA; Fernandes EG; Higashino HR; Lopes MH; Rocha VG; Costa SF; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2023; 65():e21. PubMed ID: 36946817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating.
    Haas DM; Flowers CA; Congdon CL
    Obstet Gynecol; 2005 Aug; 106(2):295-300. PubMed ID: 16055578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
    Díaz-Ortega JL; Bennett JV; Castañeda D; Martinez D; de Castro JF
    Vaccine; 2010 Oct; 28(44):7228-32. PubMed ID: 20800111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study.
    Ogawa T; Inoue T; Kasahara K; Konishi M; Mikasa K
    PLoS One; 2020; 15(3):e0230329. PubMed ID: 32208432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.